GSK plc 6-K, filed Oct 28, 2022
GSK plc (GSK)
6-K
2022-10-28
For: 2022-10-28
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on October 28, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
European Medicines Agency validates ViiV Healthcare's marketing
authorisation application for cabotegravir long-acting injectable
for HIV Prevention
● The
marketing application is based on results from the HPTN 083 and 084
phase IIb/III studies in which the injectable medicine, given as
few as six times per year, demonstrated superior efficacy to a
daily oral PrEP option (FTC/TDF tablets) in reducing the risk of
HIV acquisition[1],[2],[3],[4]
London, 28 October 2022 - ViiV Healthcare, the global specialist HIV
company majority owned by GSK, with Pfizer and Shionogi as
shareholders, today announced that the European Medicines Agency
(EMA) has validated the company's marketing authorisation
application (MAA) seeking approval of cabotegravir long-acting
injectable for pre-exposure prophylaxis (PrEP) to reduce the risk
of sexually acquired HIV-1. Cabotegravir long-acting for HIV
prevention is administered six times per year, after
initiation.[5]
Kimberly Smith, M.D., MPH, Head of Research & Development at
ViiV Healthcare, said: "With approximately 100,000 people in Europe
newly diagnosed with HIV each year, this submission is an important
step forward in offering expanded options for HIV
prevention.6 Long-acting
prevention options, if used appropriately and at scale, could have
the potential to transform the shape of the HIV epidemic and we
look forward to continuing to work with community groups,
governments and regulatory authorities to make this option
available for those who need it."
Submission to the EMA was supported by data from two international
phase IIb/III multicentre, randomised, double-blind, active
controlled studies, HPTN 083 and HPTN 084, which evaluated the
safety and efficacy of cabotegravir long-acting for PrEP in
HIV-negative men who have sex with men, transgender women, and
cisgender women who were at increased risk of HIV. The studies
demonstrated that cabotegravir long-acting for PrEP was superior to
daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF),
with clinical trial participants experiencing a 69% lower rate of
HIV acquisition compared to FTC/TDF tablets in HPTN 083, and a 90%
lower rate of HIV acquisition compared to FTC/TDF tablets in HPTN
084. 1,2,3,4
Cabotegravir long-acting for PrEP is currently approved in the US,
Australia and Zimbabwe as Apretude.
About cabotegravir
extended-release injectable suspension5
Cabotegravir long-acting for HIV prevention is the first and only
long-acting injectable PrEP option proven superior to daily oral
FTC/TDF in reducing HIV acquisition.
Cabotegravir long-acting for PrEP is an integrase strand transfer
inhibitor (INSTI). INSTIs, like cabotegravir extended-release
injectable suspension, inhibit HIV replication by preventing the
viral DNA from integrating into the genetic material of human
immune cells (T-cells). This step is essential in the HIV
replication cycle and is also responsible for establishing chronic
disease.
Cabotegravir long-acting for PrEP is provided as an injection
administered six times per year and is initiated with a single 600
mg (3-ml) injection given one month apart for two consecutive
months. After the second initiation injection, the recommended
continuation injection dose is a single 600 mg (3-ml) injection
given every two months. Vocabria (cabotegravir oral tablets) may be
administered for approximately one month before initiating the
first injection to assess the tolerability of the
medicine.
About HPTN 083
(NCT02720094)1,3
The HPTN 083 trial is a phase IIb/III double blind non-inferiority
trial designed to evaluate the safety and efficacy of long-acting
injectable cabotegravir for HIV prevention administered every eight
weeks compared to daily oral FTC/TDF tablets (200 mg/300 mg). The
trial included the prespecified ability to test for superiority of
long-acting cabotegravir over FTC/TDF.
The trial design included an oral lead-in phase to assess
tolerability to cabotegravir before administering the intramuscular
(IM) injection. Each participant was to receive a maximum of three
years of blinded trial medication. The trial opened to enrolment in
November 2016. HPTN 083 was conducted in 4,566 HIV-negative men who
have sex with men and transgender women who have sex with men, who
had evidence of behaviour that would put them at high-risk for
sexually acquiring HIV-1. The trial is being conducted at research
centres in Argentina, Brazil, Peru, the United States, South
Africa, Thailand, and Vietnam.
Long-acting cabotegravir was found to be superior to daily oral
FTC/TDF in preventing HIV acquisition in the trial population. The
most common adverse reactions (all grades) observed in at least 1%
of subjects receiving long-acting cabotegravir were injection site
reactions, diarrhoea, headache, pyrexia, fatigue, sleep disorders,
nausea, dizziness, flatulence, and abdominal pain.
For further information on HPTN 083 please
see https://clinicaltrials.gov/ct2/show/NCT02720094.
About HPTN 084
(NCT03164564)2,4
The HPTN 084 trial is a phase III double blind superiority trial
designed to evaluate the safety and efficacy of the long-acting
injectable cabotegravir for HIV prevention administered every eight
weeks compared to daily oral FTC/TDF tablets (200 mg/300 mg) in
3,224 cisgender women who are at increased risk of HIV acquisition.
The trial design included an oral lead-in phase to assess
tolerability to cabotegravir before administering the IM injection.
HPTN 084 opened to enrolment in November 2017 and is being
conducted at research centres in Botswana, Kenya, Malawi, South
Africa, Eswatini, Uganda, and Zimbabwe.
Long-acting cabotegravir was found to be superior to daily oral
FTC/TDF in preventing HIV acquisition in the trial population. The
most common adverse reactions (all grades) observed in at least 1%
of subjects receiving long-acting cabotegravir were injection site
reactions, diarrhoea, headache, fatigue, sleep disorders, nausea,
dizziness, abdominal pain, vomiting, myalgia, and
rash.
For further information please see https://clinicaltrials.gov/ct2/show/NCT03164564.
Please see full U.S. Prescribing
Information for Apretude.
Trademarks are owned by or licensed to the ViiV Healthcare
group of companies.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in
November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to
delivering advances in treatment and care for people living with
HIV and for people who are at risk of becoming infected with
HIV. Shionogi became
a ViiV shareholder in October 2012. The company's aims are to take
a deeper and broader interest in HIV and AIDS than any company has
done before and take a new approach to deliver effective and
innovative medicines for HIV treatment and prevention, as well as
support communities affected by HIV.
For more information on the company, its management, portfolio,
pipeline, and commitment, please visit www.viivhealthcare.com.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
ViiV Healthcare enquiries:
|
|
|
|
|
Media
enquiries:
|
Catherine
Hartley
|
+44
7909 002 403
|
(London)
|
|
|
Rachel
Jaikaran
|
+44
7823 532 755
|
(London)
|
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
Analyst/Investor
enquiries:
|
|
|
|
|
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
GSK plc
ViiV Healthcare Limited
No. 3888792
No. 06876960
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
[1] Landovitz RJ, Donnell D, Clement
ME, et al. Cabotegravir for HIV Prevention in Cisgender Men and
Transgender Women. The New
England Journal of Medicine 2021;385:595-608. DOI:
10.1056/NEJMoa2101016
[2] Delaney-Moretlwe S, Hughes J,
Bock P, et al. Long acting injectable cabotegravir is safe and
effective in preventing HIV infection in cisgender women: interim
results from HPTN 084. Presented at HIV R4P
2021.
[3] Clinical Trials.gov - Safety and
Efficacy Study of Injectable Cabotegravir Compared to Daily Oral
Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For
Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and
Transgender Women Who Have Sex With Men. Available
at
https://clinicaltrials.gov/ct2/show/NCT02720094. Last accessed October
2022.
[4] Clinical Trials.gov - Evaluating
the Safety and Efficacy of Long-Acting Injectable Cabotegravir
Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in
HIV-Uninfected Women. Available at https://clinicaltrials.gov/ct2/show/NCT03164564.
Last accessed October 2022.
[5] Apretude Prescribing
Information. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Apretude/pdf/APRETUDE-PI-PIL-IFU.PDF
6 ECDC/World Health
Organisation (2021) HIV/AIDS surveillance in Europe. Available
at https://www.ecdc.europa.eu/sites/default/files/documents/2021-Annual_HIV_Report_0.pdf. Last
accessed October 2022.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
28, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|